FinBERT, a financial-language model, scores this headline as positive (92% confidence). That is the news tone only — not the full stock rating.
Stocks › TARS
Tarsus Pharmaceuticals, Inc. (TARS) stock analysis
WEAK BUY 34% confidence · analysed Oct 30, 2026
On Oct 30, 2026, our model rated Tarsus Pharmaceuticals, Inc. (TARS) WEAK BUY with 34% confidence at a price of $75.25. That means the signals lean positive, but they are mixed, so conviction is low.
Analysed price$75.25
Technical picture
The 14-day RSI is 52, close to the neutral 50 line, so momentum is balanced.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.1x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $85.25 and the swing low is $53.89; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The company reports a profit margin of -7.7% and revenue growth of +69.4%.
In its latest quarter it earned $-0.43 per share, which missed the $-0.20 analysts expected, with revenue +69.4% year over year.
Wall Street's average rating is 1.1 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $99.56.
The next earnings report is expected around Nov 3, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $75.20, a target of $83.76 (+11.4%) and a stop-loss at $68.46 (-9.0%).
That is a reward-to-risk ratio of about 1.3 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Nov 2, 2026 whatever the price does.
Entry$75.20
Target$83.76
Stop-loss$68.46
Reassess byNov 2, 2026
The model's one-paragraph read
Leans BUY — composite score +0.34 (WEAK BUY). Technicals: RSI 51.67, MACD bullish, price above SMA50. Fundamentals: margin -7.7%, revenue growth 69.4%. Financial results: YoY revenue +69.4%, last EPS surprise -115.0%, next earnings 2026-11-03. Smart Money Concepts: ranging / no clear structure, price retesting a bullish order block. FinGPT news read: positive. Suggested levels: entry $75.2, target $83.76, stop-loss $68.46, exit by 2026-11-02 (exit before next earnings (2026-11-03) -- this signal doesn't price in that report).
Past ratings for TARS
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 30, 2026 | WEAK BUY | 34% | $75.25 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on TARS
Oct 30, 2026 · Tarsus Must Show Xtemvi Can Outrun Its Pricier Retina Ambitions In Q3
- Oct 30, 2026: Tarsus Must Show Xtemvi Can Outrun Its Pricier Retina Ambitions In Q3 (Earnings Whispers)
- Oct 29, 2026: Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 (GlobeNewswire)
Frequently asked questions
Is TARS a buy right now?
As of Oct 30, 2026, our automated model rates Tarsus Pharmaceuticals, Inc. (TARS) WEAK BUY with 34% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for TARS?
The model's most recent plan targets $83.76 with a stop-loss at $68.46, from an entry near $75.20.
When does Tarsus Pharmaceuticals, Inc. report earnings next?
The next earnings report is expected around Nov 3, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.